Last updated: September 4, 2026

Ixabepilone, marketed as Ixempra by Bristol-Myers Squibb, was approved in the United States in 2007 for metastatic or locally advanced breast cancer after failure of anthracyclines, taxanes, and capecitabine. Its commercial profile deteriorated because of peripheral neuropathy, myelosuppression, hepatic restrictions, limited survival differentiation, and competition from low-cost generic chemotherapy. BMS discontinued U.S. marketing, and the U.S. New Drug Application was later withdrawn. Ixabepilone is now a legacy oncology asset with limited commercial value, no meaningful U.S. biosimilar risk, and generic-entry risk that is primarily historical rather than an active market event.

What is ixabepilone and how was it used clinically?

Ixabepilone is a semi-synthetic epothilone analog that stabilizes microtubules, producing an antineoplastic effect similar to taxanes. Its principal development objective was to treat breast cancers resistant to anthracyclines and taxanes.

The U.S. label covered two uses:

Use	Regimen	Patient population
Combination therapy	Ixabepilone plus capecitabine	Locally advanced or metastatic breast cancer after failure of an anthracycline and a taxane, or when further anthracycline therapy was inappropriate
Monotherapy	Ixabepilone alone	Locally advanced or metastatic breast cancer after failure of an anthracycline, a taxane, and capecitabine, or when capecitabine was inappropriate

The labeled ixabepilone dose was 40 mg/m² intravenously over three hours every three weeks. The formulation contained polyoxyethylated castor oil, which required a premedication regimen to reduce hypersensitivity reactions.[1]

How effective was ixabepilone?

In the pivotal phase 3 trial supporting the combination indication, ixabepilone plus capecitabine improved median progression-free survival compared with capecitabine alone. The improvement was statistically significant but modest in absolute terms. The trial did not establish a clear overall-survival advantage in the broader population.[2]

The monotherapy indication was supported by response rates in heavily pretreated patients rather than by a large randomized survival benefit. This positioned ixabepilone as a salvage therapy rather than a preferred earlier-line treatment.

When did ixabepilone receive FDA approval and lose U.S. exclusivity?

The FDA approved Ixempra on October 16, 2007. The approval was based on activity in patients with advanced breast cancer who had exhausted several standard therapies.[3]

Milestone	Date
U.S. FDA approval	October 16, 2007
Likely new-chemical-entity exclusivity endpoint	2012
Initial commercial period	2007-2014
BMS U.S. marketing discontinuation reported	Approximately 2015
U.S. NDA withdrawal	2020
Historical core patent protection	Approximately 2021, subject to patent-term adjustments and listing history

Ixabepilone did not receive orphan-drug exclusivity for its broad breast-cancer indications. Its commercial protection therefore depended mainly on statutory NCE exclusivity, listed patents, and the practical complexity of developing and approving an injectable generic.

The FDA’s Drugs@FDA records identify the Ixempra NDA as withdrawn for reasons other than safety or effectiveness. That distinction matters: the withdrawal ended the active U.S. regulatory product pathway but did not constitute an FDA finding that ixabepilone was ineffective.[4]

What patents protected ixabepilone?

Ixabepilone’s principal U.S. patent estate was built around composition-of-matter and treatment claims covering epothilone analogs and their use in cancer therapy.

Core composition and method patents

Historical U.S. patent records and Orange Book listings associated ixabepilone with patents including:

Patent	General subject matter	Historical relevance
U.S. Patent No. 6,242,469	Epothilone derivatives and related compounds	Principal composition-of-matter protection associated with ixabepilone
U.S. Patent No. 7,598,374	Treatment-related claims involving ixabepilone or related epothilone compounds	Later-stage method-of-use protection

Patent expiry dates depend on terminal disclaimers, patent-term adjustment, patent-term extension, and the specific listed claim. The core composition protection was generally treated as having expired around 2021. Later method claims could have extended nominal protection into the middle of the decade, but their practical value was constrained by the withdrawal of the U.S. NDA and the absence of a substantial marketed product.[5][6]

What formulation patents protected Ixempra?

Ixempra used a lyophilized intravenous formulation with a separate diluent and infusion preparation process. The formulation addressed ixabepilone’s solubility and administration requirements rather than creating an oral or long-acting product.

The principal commercial barriers were:

Intravenous manufacturing under sterile conditions.
Control of the active pharmaceutical ingredient and related impurities.
Reproducible reconstitution and infusion performance.
Management of the formulation’s excipient system.
Demonstration of pharmaceutical equivalence and bioequivalence for an injectable generic.

Formulation and process claims could delay or complicate generic development, but they did not create the same strategic barrier as a durable composition patent. Once core compound protection expired and the product was no longer commercially supported in the U.S., the value of formulation patents declined sharply.

What is the Orange Book status of Ixempra?

The commercial and regulatory status of Ixempra is inactive in the United States. The NDA withdrawal means that the product is not an actively marketed FDA-approved reference product for ordinary U.S. commercial purposes.

Orange Book and FDA issue	Assessment
Reference product	Ixempra, ixabepilone injection
Sponsor	Bristol-Myers Squibb
U.S. NDA	022307
Current U.S. marketing position	Withdrawn/discontinued
Active U.S. exclusivity	None
Core patent position	Historical protection largely expired
Generic competition	No major marketed U.S. generic presence identified
Biosimilar pathway	Not applicable

The absence of an active reference product reduces the commercial incentive for an ANDA applicant. A generic developer would face a limited market, clinical substitution challenges, and the need to support sterile injectable manufacturing for a therapy that has lost clinical share to newer breast-cancer treatments.

How strong was the ixabepilone patent estate?

The patent estate was moderate during the original launch period and weak as a current commercial asset.

Strengths

A composition-of-matter position supported early exclusivity.
The molecule had a differentiated mechanism from some competing cytotoxic agents.
Injectable generic development required more manufacturing work than an ordinary oral tablet.
Method-of-use claims targeted taxane-resistant and heavily pretreated breast cancer.

Weaknesses

Patent life was limited by the long clinical-development period.
The commercial indication was narrow.
Method-of-use claims were difficult to enforce against off-label use.
The product’s toxicity limited adoption.
The eventual U.S. NDA withdrawal reduced the economic value of later-expiring claims.
Breast-cancer treatment moved toward targeted therapies, antibody-drug conjugates, hormonal agents, and immuno-oncology combinations.

The estate was therefore stronger as a launch-protection platform than as a long-term lifecycle-management asset. There is no significant evidence that BMS converted ixabepilone into a durable second-generation product through oral delivery, a novel formulation, or a new tumor indication.

Which companies challenged ixabepilone patents?

No major, commercially consequential Paragraph IV challenge is associated with a U.S. generic ixabepilone launch. Publicly visible patent litigation did not produce a market-shaping settlement comparable with high-value oral oncology products.

The absence of a prominent Paragraph IV dispute does not mean that generic entry was legally impossible. It indicates that the expected market opportunity was insufficient to support a large patent challenge after the product’s commercial decline.

What generic launch risks existed?

A potential ANDA applicant would have faced four principal risks:

Reference-product risk. The withdrawal of the NDA weakened the commercial basis for a conventional generic launch.
Injectable-equivalence risk. Ixabepilone required sterile parenteral manufacturing and demonstrated equivalence.
Market-size risk. Use was concentrated in late-line metastatic breast cancer.
Clinical-substitution risk. Oncologists had alternatives with stronger contemporary adoption and better-aligned treatment sequencing.

The theoretical launch scenario after patent expiry was therefore unattractive. Even a successful generic would have entered a small and shrinking market with low expected pricing power.

How did ixabepilone compare with competing breast-cancer drugs?

Ixabepilone competed against taxanes, capecitabine combinations, vinorelbine, gemcitabine, eribulin, and later targeted agents.

Drug or class	Commercial advantage over ixabepilone
Paclitaxel and docetaxel	Established efficacy, physician familiarity, broad generic availability
Capecitabine	Oral administration and low-cost generic supply
Eribulin	A defined later-line breast-cancer position and simpler commercial identity
Vinorelbine and gemcitabine	Familiar generic chemotherapy options
Trastuzumab-based therapy	Strong value in HER2-positive disease
Antibody-drug conjugates	Higher activity in selected biomarker-defined populations
CDK4/6 inhibitors	Dominant role in hormone-receptor-positive disease
Immune checkpoint combinations	Expansion into selected triple-negative disease

Ixabepilone’s main clinical advantage was activity in patients with taxane-resistant disease. Its disadvantage was that the same heavily pretreated population often had poor tolerance for additional neuropathy and marrow suppression.

What caused ixabepilone’s commercial decline?

Ixabepilone’s market trajectory followed a common late-line oncology pattern: regulatory approval was achieved, but the product failed to build a durable franchise.

Clinical and safety pressure

The most important adverse events included peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, fatigue, nausea, diarrhea, and hepatotoxicity. The label included a contraindication or strong restriction involving hepatic impairment, particularly when ixabepilone was combined with capecitabine.[1]

Peripheral neuropathy was commercially important because many eligible patients had already received taxanes. Cumulative neurotoxicity reduced treatment persistence and limited use in earlier lines.

Limited differentiation

The capecitabine combination improved progression-free survival, but the magnitude of benefit did not establish ixabepilone as a standard replacement for taxanes. The product was often reserved for patients with limited remaining options.

Generic pricing pressure

Ixabepilone entered an environment where taxanes and other cytotoxic agents were available at low cost. A branded intravenous chemotherapy product needed a substantial clinical or operational advantage to maintain premium pricing. Ixabepilone did not establish that advantage.

Changes in breast-cancer treatment

The market shifted toward biomarker-selected and mechanism-specific treatment. HER2-directed therapy, endocrine therapy combined with CDK4/6 inhibitors, PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates narrowed the addressable population for a broad cytotoxic salvage product.

What was the financial trajectory of ixabepilone?

BMS did not report Ixempra as a consistently separate material revenue line in its public financial disclosures. That limits precise reconstruction of product-level sales and prevents a reliable public calculation of peak revenue, cumulative revenue, or product-level profit.

The available commercial trajectory is clear in direction:

Period	Financial and market position
2007-2008	Launch into a large breast-cancer market with expectations for use after taxane failure
2009-2011	Adoption constrained by neuropathy, myelosuppression, hepatic limitations, and modest differentiation
2012-2014	Pressure from generic chemotherapy and expanding targeted treatments
2015 onward	U.S. commercial relevance declined after BMS discontinued marketing
2020 onward	U.S. NDA withdrawal removed the product from active commercial development

Ixabepilone did not become a material BMS growth driver comparable with the company’s major cardiovascular, immunology, oncology, or virology brands. The financial impact of discontinuation was therefore more likely to involve portfolio simplification and removal of maintenance costs than a material loss of group revenue.

What licensing deals affected ixabepilone?

Ixabepilone originated from epothilone research associated with the Scripps Research Institute and Bristol-Myers Squibb. BMS obtained commercial rights through its development and licensing arrangements connected with the epothilone platform.

No major late-stage licensing transaction appears to have revived ixabepilone after U.S. commercial discontinuation. There is also no significant public evidence of a strategic regional relaunch, a formulation license, or an oncology-combination deal that materially changed its financial outlook.

What is the biosimilar and generic risk for ixabepilone?

Biosimilar risk is effectively zero because ixabepilone is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic ixabepilone injection.

That generic risk is economically limited:

Core patent protection has historically expired.
The U.S. reference NDA is withdrawn.
The target population is small and late-line.
Hospital purchasing favors low-cost alternatives.
Sterile injectable production raises development and compliance costs.
Physicians have moved toward newer targeted and antibody-drug conjugate therapies.

The more important commercial risk was not generic entry itself. It was therapeutic displacement before generic entry became attractive.

What patent litigation and settlement agreements affected ixabepilone?

No major publicly documented patent litigation or Paragraph IV settlement materially shaped U.S. ixabepilone competition. The lack of a significant settlement is consistent with the product’s limited market value and declining commercial position.

Any current diligence should distinguish between:

Historical patent expiry.
NDA withdrawal.
Discontinuation of U.S. marketing.
Absence of a major generic launch.
Lack of meaningful active litigation.

These are separate legal and commercial events.

What geographic markets remain relevant for ixabepilone?

Ixabepilone’s strongest regulatory and commercial relevance was in the United States. Its international opportunity was narrower because reimbursement systems and treatment guidelines placed greater emphasis on cost-effectiveness and established generic chemotherapy.

The European regulatory position was less favorable than the U.S. position, and ixabepilone did not achieve a comparable global franchise. Any remaining use would be country-specific, dependent on local authorization, hospital procurement, and physician preference.

Geographic value is therefore limited. A company acquiring ixabepilone rights would not be buying a global growth product. It would be acquiring a legacy oncology asset with possible niche value in selected markets, subject to local regulatory and supply conditions.

What manufacturing and intellectual-property barriers remain?

The most meaningful remaining barriers are operational rather than patent-based.

Manufacturing barriers

Sterile injectable production.
Complex reconstitution and infusion preparation.
Stability control for the lyophilized product.
Management of excipient-related hypersensitivity risk.
Consistent impurity and particulate control.
Small-batch economics in a declining oncology market.

Intellectual-property barriers

Historical composition claims are largely expired.
Residual method-of-use claims have limited enforcement value where prescribing is not indication-specific.
Formulation and process claims may complicate development but are unlikely to support durable premium pricing.
No major active exclusivity barrier remains in the United States.

Key Takeaways

Ixabepilone was approved by the FDA in 2007 for heavily pretreated advanced breast cancer.
Its commercial performance was limited by neuropathy, marrow toxicity, hepatic restrictions, and modest clinical differentiation.
BMS discontinued U.S. marketing, and the NDA was withdrawn in 2020.
Historical core patent protection extended approximately into 2021, with later method-related claims potentially lasting longer.
No major Paragraph IV challenge or settlement reshaped the U.S. market.
Biosimilar risk is irrelevant; generic injectable competition is the applicable framework.
The product generated no publicly disclosed, consistently separate material revenue stream for BMS.
Current value is concentrated in residual international use, legacy intellectual property, and possible niche manufacturing opportunities rather than in a scalable branded franchise.

FAQs About Ixabepilone Exclusivity and Commercial Value

Is ixabepilone still FDA approved in the United States?

The Ixempra NDA was withdrawn, and the product is not an actively marketed U.S. reference product.

Can a company launch a generic ixabepilone injection?

A generic developer could theoretically pursue an abbreviated approval pathway, but the withdrawn reference-product status, sterile manufacturing requirements, and limited demand substantially reduce the commercial incentive.

Did ixabepilone receive pediatric exclusivity?

No material pediatric-exclusivity extension is generally associated with the product’s U.S. commercial history.

Was ixabepilone approved for ovarian or lung cancer?

Its principal U.S. approval was for locally advanced or metastatic breast cancer. Other oncology studies did not create a commercially important additional indication.

What would make ixabepilone commercially attractive again?

A renewed opportunity would require a new formulation, a biomarker-defined responder population, convincing combination data, or a regulatory pathway in a market where newer targeted therapies are unavailable or unaffordable. No such program has materially re-established the product.

References

U.S. Food and Drug Administration. (2007). Ixempra (ixabepilone) prescribing information.
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X., Lim, R., & others. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 25(33), 5210-5217.
U.S. Food and Drug Administration. (2007, October 16). FDA approves Ixempra for advanced breast cancer.
U.S. Food and Drug Administration. (2020). Drugs@FDA: Ixempra NDA 022307.
U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,242,469, Epothilone derivatives.
U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,598,374.
Bristol-Myers Squibb Company. (2008-2015). Annual reports and Form 10-K filings.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	114
What excipients (inactive ingredients) are in ixabepilone?	ixabepilone excipients list
DailyMed Link:	ixabepilone at DailyMed

Sponsor	Phase
Allarity Therapeutics	Phase 2
R-Pharm-US, LLC	Phase 2
R-Pharm US, Inc.	Phase 2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007	⤷ Start Trial	⤷ Start Trial
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Summary for ixabepilone

Recent Clinical Trials for ixabepilone

Anatomical Therapeutic Chemical (ATC) Classes for ixabepilone

Paragraph IV (Patent) Challenges for IXABEPILONE